AXLRx Book a callCommission

Mid Specialty · Company profile

Regeneron

Commission a Regeneron report

By therapy area

Therapy area All areas ImmunologyPulmonology

AXLRx reports featuring Regeneron

CI · Immunology · CI Team · Launch Lead US Atopic Dermatitis Competitive Intelligence Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs. US · In-Market · Read report → DL · Immunology · CI Team · Launch Lead US Atopic Dermatitis Disease Landscape US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment. US · In-Market · Read report → P&HTA · Immunology · Market Access · Medical Affairs US Atopic Dermatitis Payer & HTA Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected. US · In-Market · Read report → CI · Pulmonology · CI Team · Launch Lead US COPD Competitive Intelligence Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier. US · In-Market · Read report →